Predominant development of mature and functional human NK cells in a novel human IL-2 - Producing transgenic NOG mouse

Journal of Immunology

Volumn 194, Issue 7, 2015, Pages 3513-3525

  Katano, Ikumi ^a,b   Takahashi, Takeshi ^a   Ito, Ryoji ^a   Kamisako, Tsutomu ^a   Mizusawa, Takuma ^a   Ka, Yuyo ^a   Ogura, Tomoyuki ^a   Suemizu, Hiroshi ^a   Kawakami, Yutaka ^b   Ito, Mamoru ^a  

^a CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD94 ANTIGEN; CHEMOKINE RECEPTOR CCR4; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; GRANZYME A; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MOGAMULIZUMAB; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; MEMBRANE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IL 2 GENE; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; LEUKEMIA; LYMPHOCYTE DIFFERENTIATION; LYMPHOMA CELL LINE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL INOCULATION; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; CYTOLOGY; CYTOTOXICITY; DISEASE MODEL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, SURFACE; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; MICE, TRANSGENIC; NEOPLASMS; PHENOTYPE; RECEPTORS, KIR;

EID: 84925840759     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401323     Document Type: Article

References (35)

1. Spits, H., and J. P. Di Santo. 2011. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12: 21-27.
2. Timonen, T. 1997. Natural killer cells: endothelial interactions, migration, and target cell recognition. J. Leukoc. Biol. 62: 693-701.
3. Shiokawa, M., T. Takahashi, A. Murakami, S. Kita, M. Ito, K. Sugamura, and N. Ishii. 2010. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice. Biochem. Biophys. Res. Commun. 399: 733-737.
4. Hiramatsu, H., R. Nishikomori, T. Heike, M. Ito, K. Kobayashi, K. Katamura, and T. Nakahata. 2003. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood 102: 873-880.
5. Huntington, N. D., N. Legrand, N. L. Alves, B. Jaron, K. Weijer, A. Plet, E. Corcuff, E. Mortier, Y. Jacques, H. Spits, and J. P. Di Santo. 2009. IL-15 transpresentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 206: 25-34.
6. Strowig, T., O. Chijioke, P. Carrega, F. Arrey, S. Meixlsperger, P. C. Rämer, G. Ferlazzo, and C. Münz. 2010. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood 116: 4158-4167.
7. Chen, Q., M. Khoury, and J. Chen. 2009. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc. Natl. Acad. Sci. USA 106: 21783-21788.
8. Willinger, T., A. Rongvaux, T. Strowig, M. G. Manz, and R. A. Flavell. 2011. Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. Trends Immunol. 32: 321-327.
9. Shultz, L. D., M. A. Brehm, J. V. Garcia-Martinez, and D. L. Greiner. 2012. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12: 786-798.
10. Ito, R., T. Takahashi, I. Katano, and M. Ito. 2012. Current advances in humanized mouse models. Cell. Mol. Immunol. 9: 208-214.
11. Lopez-Vergès, S., J. M. Milush, S. Pandey, V. A. York, J. Arakawa-Hoyt, H. Pircher, P. J. Norris, D. F. Nixon, and L. L. Lanier. 2010. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116: 3865-3874.
12. Freud, A. G., A. Yokohama, B. Becknell, M. T. Lee, H. C. Mao, A. K. Ferketich, and M. A. Caligiuri. 2006. Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med. 203: 1033-1043.
13. Caligiuri, M. A., A. Zmuidzinas, T. J. Manley, H. Levine, K. A. Smith, and J. Ritz. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171: 1509-1526.
14. Nagler, A., L. L. Lanier, S. Cwirla, and J. H. Phillips. 1989. Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. 143: 3183-3191.
15. Cooper, M. A., T. A. Fehniger, S. C. Turner, K. S. Chen, B. A. Ghaheri, T. Ghayur, W. E. Carson, and M. A. Caligiuri. 2001. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97: 3146-3151.
16. Lanier, L. L., A. M. Le, J. H. Phillips, N. L. Warner, and G. F. Babcock. 1983. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J. Immunol. 131: 1789-1796.
17. Jacobs, R., G. Hintzen, A. Kemper, K. Beul, S. Kempf, G. Behrens, K. W. Sykora, and R. E. Schmidt. 2001. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur. J. Immunol. 31: 3121-3127.
18. Ito, A., T. Ishida, H. Yano, A. Inagaki, S. Suzuki, F. Sato, H. Takino, F. Mori, M. Ri, S. Kusumoto, et al. 2009. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol. Immunother. 58: 1195-1206.
19. Trinchieri, G., M. Matsumoto-Kobayashi, S. C. Clark, J. Seehra, L. London, and B. Perussia. 1984. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med. 160: 1147-1169.
20. Lanier, L. L., D. W. Buck, L. Rhodes, A. Ding, E. Evans, C. Barney, and J. H. Phillips. 1988. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J. Exp. Med. 167: 1572-1585.
21. Miller, J. S., C. Verfaillie, and P. McGlave. 1992. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. Blood 80: 2182-2187.
22. Jacobs, R., M. Stoll, G. Stratmann, R. Leo, H. Link, and R. E. Schmidt. 1992. CD16-CD56+ natural killer cells after bone marrow transplantation. Blood 79: 3239-3244.
23. Chklovskaia, E., P. Nowbakht, C. Nissen, A. Gratwohl, M. Bargetzi, and A. Wodnar-Filipowicz. 2004. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand. Blood 103: 3860-3868.
24. Dulphy, N., P. Haas, M. Busson, S. Belhadj, R. Peffault de Latour, M. Robin, M. Carmagnat, P. Loiseau, R. Tamouza, C. Scieux, et al. 2008. An unusual CD56 (bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J. Immunol. 181: 2227-2237.
25. Vukicevic, M., Y. Chalandon, C. Helg, T. Matthes, C. Dantin, B. Huard, C. Chizzolini, J. Passweg, and E. Roosnek. 2010. CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. Eur. J. Immunol. 40: 3246-3254.
26. Caligiuri, M. A., C. Murray, M. J. Robertson, E. Wang, K. Cochran, C. Cameron, P. Schow, M. E. Ross, T. R. Klumpp, R. J. Soiffer, et al. 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 91: 123-132.
27. Klimosch, S. N., Y. Bartel, S. Wiemann, and A. Steinle. 2013. Genetically coupled receptor-ligand pair NKp80-AICL enables autonomous control of human NK cell responses. Blood 122: 2380-2389.
28. Ferlazzo, G., D. Thomas, S. L. Lin, K. Goodman, B. Morandi, W. A. Muller, A. Moretta, and C. Münz. 2004. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172: 1455-1462.
29. Kennedy, M. K., M. Glaccum, S. N. Brown, E. A. Butz, J. L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C. R. Willis, et al. 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191: 771-780.
30. Lodolce, J. P., D. L. Boone, S. Chai, R. E. Swain, T. Dassopoulos, S. Trettin, and A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9: 669-676.
31. Suzuki, H., G. S. Duncan, H. Takimoto, and T. W. Mak. 1997. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J. Exp. Med. 185: 499-505.
32. Kim, S., J. Poursine-Laurent, S. M. Truscott, L. Lybarger, Y. J. Song, L. Yang, A. R. French, J. B. Sunwoo, S. Lemieux, T. H. Hansen, and W. M. Yokoyama. 2005. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.
33. Kim, S., J. B. Sunwoo, L. Yang, T. Choi, Y. J. Song, A. R. French, A. Vlahiotis, J. F. Piccirillo, M. Cella, M. Colonna, et al. 2008. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl. Acad. Sci. USA 105: 3053-3058.
34. Joncker, N. T., N. Shifrin, F. Delebecque, and D. H. Raulet. 2010. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J. Exp. Med. 207: 2065-2072.
35. Elliott, J. M., J. A. Wahle, and W. M. Yokoyama. 2010. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J. Exp. Med. 207: 2073-2079.